Category: Pα+ - Page 11 - Psychedelic Alpha

Read more about the article Pα+ Psychedelic Patent Analysis: A Mebufotenin Melee (Dec ’23 & Jan ’24)

Pα+ Psychedelic Patent Analysis: A Mebufotenin Melee (Dec ’23 & Jan ’24)

Post published:February 22, 2024
Post category:Psychedelic Patent Analysis Pα+

Read more about the article Pα+ Psychedelic Bulletin #156: Canada’s First Published Psilocybin Trial; University of Maryland Joins Terran’s Complaint Against Compass

Pα+ Psychedelic Bulletin #156: Canada’s First Published Psilocybin Trial; University of Maryland Joins Terran’s Complaint Against Compass

Post published:February 19, 2024
Post category:Psychedelic Bulletin Pα+

Read more about the article Pα+: Day 2 Dispatch from ‘Advancing Psychedelic Clinical Study Design’, Hosted by the Reagan-Udall Foundation for the FDA

Pα+: Day 2 Dispatch from ‘Advancing Psychedelic Clinical Study Design’, Hosted by the Reagan-Udall Foundation for the FDA

Post published:February 16, 2024
Post category:Analysis Pα+

Read more about the article Pα+: Day 1 Dispatch from ‘Advancing Psychedelic Clinical Study Design’, Hosted by the Reagan-Udall Foundation for the FDA

Pα+: Day 1 Dispatch from ‘Advancing Psychedelic Clinical Study Design’, Hosted by the Reagan-Udall Foundation for the FDA

Post published:February 14, 2024
Post category:Analysis Pα+

Read more about the article Pα+ Psychedelic Bulletin #155: MAPS Invests in Numinus, Hopes to Offer Experiential Training for MDMA Therapists

Pα+ Psychedelic Bulletin #155: MAPS Invests in Numinus, Hopes to Offer Experiential Training for MDMA Therapists

Post published:February 8, 2024
Post category:Psychedelic Bulletin Pα+

Read more about the article Interview: Compass Pathways CEO Kabir Nath Discusses Commercialisation, ‘Psychological Support’ and Competitive Landscape

Interview: Compass Pathways CEO Kabir Nath Discusses Commercialisation, ‘Psychological Support’ and Competitive Landscape

Post published:January 31, 2024
Post category:Interviews Pα+

Read more about the article Pα+ Psychedelic Bulletin #154: Public & Industry Respond to DEA’s Renewed DOI and DOC Scheduling Plan; TARA Mind Scores $8m Seed; Updates on State Psychedelics Programs

Pα+ Psychedelic Bulletin #154: Public & Industry Respond to DEA’s Renewed DOI and DOC Scheduling Plan; TARA Mind Scores $8m Seed; Updates on State Psychedelics Programs

Post published:January 26, 2024
Post category:Psychedelic Bulletin Pα+

Read more about the article Pα+: Knowledge Gaps in Psychedelic Medicalisation, According to ECNP and Regulators

Pα+: Knowledge Gaps in Psychedelic Medicalisation, According to ECNP and Regulators

Post published:January 17, 2024
Post category:Analysis Pα+

Read more about the article Pα+ Psychedelic Bulletin #153: MindMed Scraps Microdosing Program; Eagerly Anticipated Ibogaine Study Publishes; Compass Collaborates with Greenbrook; Gilgamesh’s GM-1020 Readout; and more…

Pα+ Psychedelic Bulletin #153: MindMed Scraps Microdosing Program; Eagerly Anticipated Ibogaine Study Publishes; Compass Collaborates with Greenbrook; Gilgamesh’s GM-1020 Readout; and more…

Post published:January 12, 2024
Post category:Psychedelic Bulletin Pα+

Read more about the article Pα+ Psychedelic Patent Analysis (November 2023)

Pα+ Psychedelic Patent Analysis (November 2023)

Post published:January 5, 2024
Post category:Psychedelic Patent Analysis Pα+

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.